ClinicalTrials.gg
CompletedNCT02740712DDIUpdated Jun 9, 2023

Pharmacokinetic Drug-Drug Interaction Study of Rucaparib

A Phase 1 interventional study of Caffeine and Warfarin in Neoplasms, sponsored by pharmaand GmbH. Completed at 3 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-09.

Sponsored by pharmaand GmbH · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess pharmacokinetic concentrations of multiple probes alone followed by assessment of the same drug pharmacokinetic concentrations when the patient has steady-state exposure to rucaparib followed by cycle-by-cycle treatment with rucaparib continuing until disease progression or other reason for discontinuation.

Read the detailed description

This is a Phase 1, open-label, sequential, drug-drug-interaction (DDI) study in patients with advanced solid tumors. The study will consist of 2 parts: a DDI part (Part I) and a rucaparib treatment part (Part II).

In Part I, the PK of cytochrome P450 (CYP) cocktail probes: caffeine, S-warfarin, omeprazole, and midazolam and a P-glycoprotein probe (digoxin) will be assessed with and without rucaparib treatment. Patients will receive single doses of CYP drug cocktail (caffeine, warfarin, omeprazole, and midazolam) on Day 1 and Day 12, and single doses of digoxin on Day 2 and Day 13. Continuous treatment with 600 mg rucaparib twice daily (BID) will start on Day 5 and will last until at least Day 16 of Part I.

In Part II, the treatment with rucaparib in 28-day cycles will continue until progression of disease, unacceptable toxicity, or other reason for discontinuation.

02

Conditions studied

  • Neoplasms

Browse trials for

Keywords

  • rucaparib
  • CO-338
  • Clovis
  • Clovis Oncology
  • PARP Inhibitor
  • Drug-Drug Interaction
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 17 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

pharmaand GmbH is the lead sponsor of 22 studies on the registry; none are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 10 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed advanced solid tumor
  • Have evidence of as defined by Version 1.1
  • (ECOG) performance status of 0 or 1
  • Adequate bone marrow, renal, and liver function

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with chemotherapy, radiation, antibody therapy or other immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, or experimental drugs within 14 days prior to Day 1
  • Prior treatment with any poly adenosine diphosphate ribose polymerase inhibitor (PARPi)
  • Arterial or venous thrombi (including cerebrovascular accident), myocardial infarction, admission for unstable angina, cardiac angioplasty, stenting or poorly controlled hypertension within the last 3 months prior to Screening;
  • Pre-existing duodenal stent, recent or existing bowel obstruction, and/or any gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of study drugs
  • Current use of therapeutic anticoagulation (low molecular weight heparin, oral anticoagulant agents including acetylsalicylic acid),
  • Current use of one of the probe drugs;
  • Untreated or symptomatic central nervous system (CNS) .
  • Evidence or history of bleeding disorder
  • Participation in another drug trial within 30 days prior to Day 1 (or 5 times the half-life of the drug, whichever is longer) or exposure to more than three new investigational agents within 12 months prior to Day 1;
  • Acute illness within 14 days prior to Day 1 unless mild in severity and approved by the Investigator and Sponsor's medical representative
  • Active second , i.e., patient known to have potentially fatal cancer present for which they may be (but not necessarily) currently receiving treatment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Other
    single arm probe drugs and rucaparib

    Caffeine Warfarin Vitamin K Omeprazole Midazolam Digoxin rucaparib

    Drug: Caffeine · Drug: Warfarin · Drug: Omeprazole · Drug: Midazolam · Drug: digoxin · Drug: Vitamin K · Drug: Rucaparib

Interventions

  • 200 mg (4 x 50mg) Tablet

  • 10 mg (2 x 5mg) Tablet

    Also known as: Marevan®

  • 40 mg Tablet

    Also known as: Losec®; MUPS®

  • 5 mg/mL

    Also known as: Midazolam Accord®; versed

  • .25 mg Tablet

    Also known as: lanoxin®

  • 10 mg Tablet

    Also known as: warfarin antagonist

  • 200 \& 300 mg tablet

    Also known as: rucaparib camsylate, Rubraca, CO-338

06

What researchers measure

Primary outcomes

  1. PK parameters for caffeine, S-warfarin, omeprazole, midazolam, and digoxin with and without rucaparib treatment to be calculated from the plasma concentration-time data

    Maximum plasma concentration \[Cmax\]

    Time frame: Days 1-5 and Days 12-16

  2. PK parameters for caffeine, S-warfarin, omeprazole, midazolam, and digoxin with and without rucaparib treatment to be calculated from the plasma concentration-time data

    Area under the concentration-time curve (AUC) up to time t, where t is the last time point with concentrations above the lower limit of quantitation \[AUC0-last \]

    Time frame: Days 1-5 and Days 12-16

Secondary outcomes

  1. PK parameters for caffeine, S-warfarin, omeprazole, midazolam, and digoxin with and without rucaparib treatment to be calculated from the plasma concentration-time data

    Area Under the Curve, from time zero up to infinity with extrapolation of the terminal phase \[AUC0-inf\]

    Time frame: Days 1-5 and Days 12-16

  2. Tolerability and safety of rucaparib with and without co-administration of the probe drugs assessed by incidence of Adverse Events (AEs), clinical laboratory abnormalities, and dose modifications"

    Incidence of Adverse Events (AEs), clinical laboratory abnormalities, and dose modifications

    Time frame: Days 1-16

  3. PK parameters will be calculated for rucaparib at steady-state

    Trough plasma concentration \[Ctrough\]

    Time frame: Day 7-12

  4. PK parameters will be calculated for rucaparib at steady-state

    Maximum plasma concentration during a dosing interval at steady-state \[Cmax,ss\]

    Time frame: Day 7-12

  5. PK parameters will be calculated for rucaparib at steady-state

    Time to attain maximum plasma concentration at steady-state \[tmax,ss\]

    Time frame: Day 7-12

  6. PK parameters will be calculated for rucaparib at steady-state

    Area Under the Curve over a dosing interval τ at steady-state \[AUCτ,ss\]

    Time frame: Day 7-12

  7. PK parameters for caffeine, S-warfarin, omeprazole, midazolam, and digoxin with and without rucaparib treatment to be calculated from the plasma concentration-time data

    Terminal half-life \[t1/2\]

    Time frame: Days 1-5 and Days 12-16

  8. PK parameters for caffeine, S-warfarin, omeprazole, midazolam, and digoxin with and without rucaparib treatment to be calculated from the plasma concentration-time data

    Time to attain maximum plasma concentration \[tmax\]

    Time frame: Days 1-5 and Days 12-16

  9. PK parameters for caffeine, S-warfarin, omeprazole, midazolam, and digoxin with and without rucaparib treatment to be calculated from the plasma concentration-time data

    Apparent clearance \[CL/F\]

    Time frame: Days 1-5 and Days 12-16

  10. PK parameters for caffeine, S-warfarin, omeprazole, midazolam, and digoxin with and without rucaparib treatment to be calculated from the plasma concentration-time data

    Apparent volume of distribution during terminal phase \[Vz/F\]

    Time frame: Days 1-5 and Days 12-16

Other outcomes

  1. Response will be determined using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 and tumor markers per applicable criteria for a given tumor type

    28 day cycles with response evaluation every 8 weeks(±7 days) until week 24 thereafter every 12 weeks (±14 days)

    Time frame: From cycle 1 Day 1until radiologically confirmed disease progression, death, or initiation of subsequent treatment whichever comes first up to 52 weeks

07

Study locations

3 sites
  • BioVirtus Research Site
    Kajetany, Mokra 7 05-830, Poland
  • Med Polonia
    Poznan, 60-693, Poland
  • Zachodniopomorskie Centrum Onkologii Centrum Innowacji
    Szczecin, 71-730, Poland
08

References and documents

Publications

  • Xiao JJ, Nowak D, Ramlau R, Tomaszewska-Kiecana M, Wysocki PJ, Isaacson J, Beltman J, Nash E, Kaczanowski R, Arold G, Watkins S. Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor. Clin Transl Sci. 2019 Jan;12(1):58-65. doi: 10.1111/cts.12600. Epub 2018 Dec 20. PubMed 30427584 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Mar 2017, 11 months.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 11 months is below that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2016
First posted
Apr 15, 2016
StartActual
Apr 2016
Primary completionActual
Mar 2017
CompletionActual
Sep 2019
Last update
Jun 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02740712
Lead sponsor
pharmaand GmbH
Responsible party
Sponsor
First posted
Apr 15, 2016
Start date
Apr 2016
Primary completion
Mar 2017
Completion
Sep 2019
Last update
Jun 9, 2023

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Caffeine · Warfarin · Omeprazole · Midazolam · Digoxin · Rucaparib

Start the discussion